TMC names former JLABS leader as the director of the Innovation Institute

taking control

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

The Texas Medical Center didn't have to go very far to find its new Innovation Institute director. Tom Luby, who most recently served as the site head for Johnson & Johnson Innovation's JLABS @ TMC, has been hired for the position.

"I am very excited to begin the next chapter in my journey at TMC Innovation," Luby says in a release. "My time at JLABS @ TMC has shown me the tremendous opportunity there is to work with a host of talented people and companies here in Houston. Now, I'm ready to expand my role and help take TMC Innovation as a collective unit to the next level."

Luby replaces Erik Halvorsen, who left abruptly in December. According to LinkedIn, Halvorsen is now the chief business and strategy officer for Houston-based FAR Biotech, for which he previously served on the board of directors. Lance Black, associate director at TMCx, served as the director in the interim for the past few months.

Prior to JLABS, Luby was in Boston at Johnson & Johnson and served as the new ventures lead. He has 14 years of research and design experience in the Boston area.

TMC as an organization has a lot up its sleeves, says President and CEO Bill McKeon in a release, and he trusts Luby to take the lead on innovation.

"With major developments in 2018, including the announcement of the forthcoming TMC3 translational research campus, Texas Medical Center is now on the fast track to becoming the third coast for life sciences, and TMC Innovation is a critical component in the ultimate realization of this goal," says McKeon. "Tom Luby is an outstanding individual, and his proven track record working with startups in Boston and within the walls of JLABS @ TMC will serve him well as he leads us through the next evolutionary phase of the TMC Innovation Institute."

Luby will oversee the med center's accelerator program, TMCx, which is currently in the midst of its eighth cohort.

Houston has just been named an emerging life sciences hub by CBRE. The recognition took job growth and lab space into consideration for the ranking.

Among this week's top stories is a feature on a Houston-based startup aiming to be the Uber or Lyft of personal trainers. Courtesy of Kanthaka

5 most popular innovation stories in Houston this week

Now trending

Editor's note: Houston saw big shake ups at some major innovation institutions this week, which made for some trending stories. And, per usual, readers enjoyed learning about local entrepreneurs fighting the good fight with their organizations.

Station Houston announces its transition into becoming a nonprofit

Station Houston's stakeholders voted in favor of the organization transitioning to a nonprofit. Station Houston/Facebook

Houston's startup scene just got a little more accessible. Station Houston's stakeholders voted to transition the organization to nonprofit status from the C-corp status it currently holds. The status change is effective January 1, 2019, for the acceleration hub, which is based in downtown Houston. The news was announced to its members in an email sent on December 13. Read the full story here.

Houston entrepreneur creates a network to link up with other blockchain professionals

The Houston Blockchain Alliance aims to connect and educate tech professionals in town. Getty Images

Houstonians traveling around the country might covet other cities for their mountain scapes, beaches, or more mild summers, but Mahesh Sashital envied the fact that other major cities had developed networks and organizations focused on connecting and educating tech professionals. Houston, it seems, was late to the party.

So, he decided to make his own blockchain-focused organization, and a few months ago, he launched the Houston Blockchain Alliance. Read the full story here.

3 Houston energy innovators to know this week

These energy startup leaders are the reason Houston will keep its "energy capital of the world" title. Courtesy images

Houston's known as the energy capital of the world, but it won't stay that way if the city as a whole doesn't work toward innovation. These three professionals started their own companies to improve efficiency and promote ingenuity in their fields. From drones and AI to quicker pipeline data access, this week's three innovators to know are the future of the energy industry. Read the full story here.

TMC Innovation Institute leader leaves the organization

Erik Halvorsen has reportedly left his position at the TMC Innovation Institute. Courtesy of TMC

Erik Halvorsen, director of the Texas Medical Center's Innovation Institute, has left his position, according to multiple reports.

TMC's medical device innovation team lead, Lance Black, was named as the interim replacement for Halvorsen, according to Xconomy. Black has been with TMC for almost two years. Read the full story here.

Get on-demand personal training from Houston-based app

Houston-based Kanthaka is the Uber or Lyft of personal training, and has recently expanded into the Austin market. Courtesy of Kanthaka

As a busy lawyer who traveled heavily for work, Sylvia Kampshoff found her workouts were often overlooked as she went from city to city, a casualty of long hours and a busy schedule. And, even though she did have a membership to a national gym with privileges at any of its locations, she hated the feeling of always being sold something and disliked that both the trainers and managers she worked with took very little interest in her personal needs and fitness goals.

She wanted something that allowed her to exercise with someone on her own schedule, and with people who valued customer service. That's how the idea for Kanthaka was born. Read the full story here.


Erik Halvorsen has reportedly left his position at the TMC Innovation Institute. Courtesy TMC

TMC Innovation Institute leader leaves the organization

TMC exited

Erik Halvorsen, director of the Texas Medical Center's Innovation Institute, has left his position, according to multiple reports.

TMC's medical device innovation team lead, Lance Black, was named as the interim replacement for Halvorsen, according to Xconomy. Black has been with TMC for almost two years.

Neither Halvorsen nor Black could not be reached for comment. This article will be updated as more information becomes available.

Halvorsen has lead the organization since 2015. Before that, he worked in various health technology focused roles in Boston. He oversaw TMC's accelerator program, TMCx. The program graduates around 20 companies per cohort, and there's two cohorts each year — one focused on medical devices, which just concluded with the Nov. 15 Demo Day, and the other, which is about to launch, focused on digital health. TMCx was recently given silver recognition from the Seed Accelerator Rankings Project.

In an interview with InnovationMap earlier this month, Halvorsen talked about his career and Houston's medical innovation ecosystem.

"One of the things that I knew moving to Houston from Boston was that the investment environment for life sciences wasn't as robust as Boston," he said in that interview. "I knew coming in that was going to be a bit of an issue. I also felt like we had the raw materials, that if we ran our program the right way and attracted those companies we needed, the dollars would flow. And that's really been the case."

These three entrepreneurs didn't see their careers coming. Courtesy photos

3 Houston innovators to know this week

Who's Who

The career paths of startup or innovation leaders isn't usually a direct path. All three of this week's innovators to know took a roundabout way to their current gigs, which included a leap of faith or two for each of them. If their winding careers are any indication, they've got more exciting leadership ahead.

Youngro Lee, CEO and co-founder of NextSeed

Courtesy of NextSeed

Starting off on Wall Street as a private equity lawyer, Youngro Lee knows money. And he knew when the Jobs Act went into effect several years ago, there was a huge opportunity for companies to raise money from non-accredited individual investors, rather than just the super wealthy private investors. He left his legal career to leverage this new law to start NextSeed, which is a platform for businesses to raise capital for from anybody. Read more here.

Jane Henry, founder and CEO of SeeHerWork

Courtesy of SeeHerWork

Jane Henry watched as her glove flew right off her hand when she was cleaning up after Hurricane Harvey — her house got three feet of mud, and she got the idea for her company. SeeHerWork goes above and beyond the normal "pink it and shrink it" approach to women's workwear. Henry wants to see female workers with better fitting safety gear. Read more here.

Erik Halvorsen, director of the TMC Innovation Institute

Courtesy of TMC

As a kid, Erik Halvorsen wanted to be a doctor — he even took the MCAT and was on track for med school. He decided to look into other avenues that combined his passion for medicine and his entrepreneurial spirit. As director of TMCx, he helps innovative medical technologies become standard practice in hospitals. Read more here.

Editor's note: Halvorsen reportedly left his position at TMC on December 13, 2018.

Erik Halvorsen is sparking a medical innovation revolution with TMCx. Courtesy of TMC

TMCx leader is ready for Houston's health care innovation ecosystem to fully bloom

MedTalk

Editor's note: Halvorsen reportedly left his position at TMC on December 13, 2018. The original article as it first published is below.

Erik Halvorsen describes himself as an impatient guy, which is why, rather than wait for Houston's medical startup culture to evolve to meet Boston's or Silicon Valley's, he's taking steps to change it now.

"The reality is Houston is not Boston or Silicon Valley, and it comes down to a couple things: access to capital and the pool of entrepreneurs running around," says Halvorsen, director of the TMC Innovation Institute.

But the Texas Medical Center is looking to change that in the health care sector with TMCx, its accelerator.

TMCx was recently given silver recognition from the Seed Accelerator Rankings Project. While it's an impressive feat, Halvorsen envisions TMCx rise through the ranks of that award over the next few years.

"For us, we're kind of competing with ourselves to be as good as we possibly can be."

TMCx graduates around 20 companies per cohort, and there's two cohorts each year — one focused on medical devices, which just concluded with the Nov. 15 Demo Day, and the other, which is about to launch, focused on digital health.

InnovationMap: How did you get your start in your industry?

Erik Halvorsen: From as young as I can remember, I wanted to be a medical doctor. Fast forward, all through undergraduate, I was pre-med. Took the MCAT, scored in the 99 percentile, but when it came time to apply to medical school, I chose not to. I ended up applying to a "tweener program" at the Medical College of Virginia in Richmond, and they had these master's programs where you would take all the first year's classes of medical school and do research in a particular discipline. I was doing research in biochemistry. I go through that whole program, and then I still wasn't sure I wanted to be a doctor or go to medical school, but I liked research. I got offered a full scholarship to do a Ph.D. program at the University of Virginia, but I didn't love being in the lab. I found an ad somewhere about an internship at the UVA Patent Foundation. It was basically taking early stage innovation, discoveries, and IP out of universities and medical centers and turning them into products, and what that's look like — whether it was startup companies or corporate partners, and that's when the lightbulb went off for me. I was really good at speaking the science to the business side, and then speaking the business and finance side to the scientists and doctors. The rest of my career became some version of playing in that in between space in helping translate ideas to ultimately get to the big companies and ultimately in the market to help patients.

IM: In your role at TMCx, you oversee the accelerator and what companies make it in. What does TMCx look for in its cohort?

EH: What we're looking for is what we think is cutting edge, and truly innovative addressing an unmet need. We consult with a lot of the hospitals here. I ask them what's keeping them up at night. That list helps me select the companies. If I see companies that are making cool products that meet one of these unmet needs in TMC, then I know that company will get traction if they were in town, and that's important.

IM: What's the process of picking the companies?

EH: We'll get 200 to 300 applications and interview about 75 companies for the 20 to 25 spots. When we interview, we get at what is their understanding of the current practice, competitive landscape, etc. It's also a good chance for us to glean a little bit of the personality of the teams we're bringing in. We learned a long time ago that we don't want to work with assholes. We go a long way to find the people who are in it for the right reasons. You have to be really smart and confident — you've got to be pretty self confident if you're think you're bringing a solution to a problem that no one has success doing before. But it has to be self confidence without arrogance.

IM: What's the economic impact of the accelerator?

EH: I think we're clearly a major piece of the Houston ecosystem. JLabs has 50 companies under their roof, and when you add TMCx and the coworking space, we have about 100 health care companies under our roof. When you think about the companies that came through our program, that's a total of 250 companies. Those companies are important to the ecosystem because they are out there telling the world about Texas, the medical center, and Houston. Their word of mouth is the reason we see the volume and the quality of the applications going up each year. A lot of our companies choose to stay in Houston.

IM: What sets TMCx apart from its competition?

EH: We don't take equity. That sets us apart. I think this is a major reason we've been able to attract companies that are more advanced — still startups, just far down the path. Those of the kinds of companies who would never consider an accelerator program that asks them to give up equity.

IM: Where does Houston's innovation sector have room for improvement?

EH: One of the things that I knew moving to Houston from Boston was that the investment environment for life sciences wasn't as robust as Boston. I knew coming in that was going to be a bit of an issue. I also felt like we had the raw materials, that if we ran our program the right way and attracted those companies we needed, the dollars would flow. And that's really been the case.

Another area we have to grow is international collaborations. We already have a high percentage of international applicants, but now we're trying to build these biobridges to other ecosystems where we can collaborate on two areas: research and innovation commercialization.

IM: What all are you excited about seeing from TMC3?

EH: I think it's really unique to Houston to bring all of these elements together in what I think is a well-designed manner. It will really transform the city. You're going to have big industry down there — a lot of those conversations are still ongoing. I mean, 116,000 medical employees and 10 million patients a year, these big health care companies want to be close to that.

This will be another way we can accelerate what we learn in the lab to treatment for patients. I'm really excited about it, and I think the startup companies we continue to bring to Houston and nurture in the TMC Innovation Institute will be a major part of bridging that gap between research and discovery to the big companies that will bring that product to market.

IM: What advice do you have for health-related startup companies?

EH: There are plenty of studies that have been done that have shown that the main reason companies fail is that there's no market for their product — and that's industry agnostic, but it's definitely true in health care. What we spend a lot of time in our program is helping the companies evaluate that and understand what their product market is — and really validating that people are going to use it and, more importantly, people are going to pay for it.

My advice would be not to just assume there's a need. Go figure out how to validate that it's a better technology and that people will use it and buy it.

------

Portions of this interview have been edited.

TMCx was nationally recognized by Seed Accelerator Rankings Project. Courtesy of TMCx

TMCx receives national award for unique startup accelerator program

x marks the spot

The Texas Medical Center has once again received national acclaim — this time, for its innovation.

Seed Accelerator Rankings Project selected TMCx for a "Silver" distinction in its 2018 awards. SARP evaluated accelerators' success and selected 25 honorees in four categories — Platinum Plus, Platinum, Gold, and Silver. The distinction is aimed to help startups navigate accelerators and find the ones of quality.

SARP objectively measures the impact of these accelerator programs, says Erik Halvorsen, director of the TMC Innovation Institute. There simply isn't non-biased information about accelerators out there. Most startups are forced to rely on marketing materials from the programs.

"One of the things I say often is, 'If you see one accelerator, you've seen one accelerator,' meaning they are all different," Halvorsen says. "There are so many out there, and it can be confusing for startups who think they are all the same."

Now in its fifth year, SARP collected sensitive information, such as fundraising and valuations, and evaluated each accelerator to select the top 25.

The TMCx accelerator program has two cohorts a year, alternating between digital health and medical device focuses. Currently, TMCx has 23 medical device companies participating in the accelerator. Halvorsen says what sets TMCx apart is its focus on medicine, but also the fact that the accelerator doesn't take equity of its companies. Other programs require anywhere from 3 to 7 percent equity in the company in exchange for participation.

"I think this is a major reason we've been able to attract companies that are more advanced — still startups, just further down the path. Those are the kinds of companies who would never consider an accelerator program that asks them to give up equity."

This is the first year TMCx has made it on to the SARP listing, but Halvorsen says it won't be the last.

"I love the fact that there's still a couple levels above where we're ranked, so we definitely have something to shoot for as we grow and improve our program," he says. "For us, we're kind of competing with ourselves to be as good as we possibly can be."

TMCx's fall cohort participants showcase their work in a final presentation called Demo Day, which is on November 14.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings